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The multifunctional IVa2 protein is essential for adenovirus replication [J. Virol. 77 (2003) 3586], but the relative importance of the
transcriptional and encapsidation functions is unknown. As part of a study of IVa2 function, we created a set of mutations in the IVa2 gene in
the correct location in the viral genome. Unexpectedly, an opal stop codon at position 6 was recovered in virus twice. Isolate #2 showed
defective viral replication, but produced late proteins at almost wild-type levels. Analysis of IVa2 mRNA showed an additional species, larger
and more abundant than the equivalent wild-type species. It was a hybrid of the 5V UTR of L3 23 kDa attached to the IVa2 second exon, so that
M75 is the 5V proximal methionine. This mRNA arises from a corresponding hybrid DNA, present in the virus stock. A protein off40 kDa,
consistent with translation from the hybrid mRNA, was detected. It is able to bind to the packaging sequence and to the MLP downstream
elements (DE1/2). Isolate #8 was more defective in replication than #2. No hybrid mRNA or DNAwas detected, but it also produces a 40 kDa
isoform, which is present in wild-type-infected cells. Mutational analysis of M75 and M101 revealed that the 40 kDa isoform is produced by
initiation at Met75. This might be the origin of the previously unidentified 40 kDa factor present in the heterodimer DEF-A, which binds to
DE1 and DE2a.
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Adenovirus transcription follows a well-characterized
temporal program. Shortly after the viral core reaches the
nucleus, the E1A gene is transcribed and differentially
spliced into two mRNAs, the translation products of which
stimulate transcription from the other early promoters E1B,
E2, E3, and E4 and also the major late promoter (MLP). At
this early stage, the MLP is active at low levels and
transcription proceeds to the L3 region of the genome, but
the only spliced mRNA produced is that encoding the L1 52/
55 kDa protein (Nevins and Wilson, 1981). Following
synthesis of the E2 mRNAs and proteins, DNA replication
begins, and the MLP is activated. This activation specifically
requires replication initiation and not its maintenance
(Thomas and Mathews, 1980). However, although DNA
replication is necessary for late phase activation of the0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: csy1@columbia.edu (A. Pardo-Mateos).MLP, it may not be sufficient. Activation may also require
the expression of the viral IVa2 protein, which is detected
shortly after DNA replication begins, and binds to the MLP
DE1 and DE2 transcription elements (Tribouley et al., 1994).
In combined infection–transfection experiments, this bind-
ing was necessary for high levels of transcription from a
reporter plasmid (Lutz and Kedinger, 1996; Monde´sert et al.,
1992; Tribouley et al., 1994). Despite these advances, the
precise mechanism of late phase activation of the MLP is not
understood.
The structure and function of the MLP has been studied
intensively using a wide range of genetic and biochemical
methods (reviewed Young, 2003). Several transcription
elements, and the corresponding binding proteins that regu-
late expression of the MLP, have been identified. Among
these, there are two downstream elements, DE1 and DE2
contained within the first intron of the MLTU (Jansen-Durr et
al., 1989; Leong et al., 1990; Mansour et al., 1986; Mon-
de´sert et al., 1992). These downstream elements were first
identified when, during the construction of Ad-SV40 hybrid
virus, it was observed that insertion of SV40 sequences at
+33 of the MLTU diminished transcription from this pro-
Fig. 1. Mutations in the IVa2 protein and the motifs in the WT protein.
NoLS: nucleolus localization signal at amino acids 50–136; NLS: nuclear
localization signal at 432–449; DBD: DNA binding domain at 58–100 and
at 357–449; H1: putative helix 1 at 79–98; H2: putative helix 2 at 413–32;
A box: consensus Walker motif A box at 171–178; B box: putative Walker
motif B box at 275–286; ^: splicing. Mutation or mutant name is shown to
the left of the diagram.
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effect was located by DNAse foot-printing analysis (Jansen-
Durr et al., 1989) and its importance in transcription con-
firmed by an ectopic placement in the E3 region of a MLP-h-
globin cassette that showed lower levels of transcription
when these elements were mutated (Leong et al., 1990).
IVa2 was identified as one of the components of the protein
complexes that bound to the downstream elements (Tribouley
et al., 1994). DE1 is bound by DEF-A (a heterodimer of the
IVa2 protein and an unknown protein of 40 kDa apparent
molecular weight) and DE2 is bound in its 5V half by DEF-B
(a homodimer of IVa2 protein) and in its 3V half by DEF-A.
Although the catalog of transcription elements is exten-
sive, their precise role in vivo is not fully understood. Thus,
many of the MLP elements were shown to have redundant
functions because mutations of one element frequently did
not show a significant effect alone, but did do so when
coupled with a mutation in another element (Reach et al.,
1990; Song and Young, 1998). Significantly, a multiple
mutation in DE1 had no effect on viral replication either
alone or in combination with a multiple mutation in UPE
(Reach et al., 1991). Thus, the importance of the IVa2 protein
in transcription in vivo is not clear. Nevertheless, physiolog-
ical evidence points to an important role. IVa2 protein is first
detected at 12 h.p.i. (Gustin et al., 1996; Winter and
D’Halluin, 1991) and its transcript is only detected from
viral genomes that have undergone replication (Binger and
Flint, 1984). The IVa2 promoter is bound by a cellular
repressor that is titrated away when replication creates
multiple copies of the template (Huang et al., 2003; Lin
and Flint, 2000). Because IVa2 protein is expressed only
after initiation of DNA replication has taken place, binds the
DE1 and DE2 elements of the MLP, and the MLP is also only
fully activated after replication, a plausible hypothesis is that
it plays a role in the early to late switch in transcription.
More recent evidence has shown that IVa2 protein is
multifunctional. It is able to bind to the L1 52/55 kDa protein
(Gustin et al., 1996), a protein involved in viral assembly
(Gustin and Imperiale, 1998; Hasson et al., 1989), and it is
also able to bind to the packaging signal (Zhang and
Imperiale, 2000). A virus lacking expression of IVa2 fails
to form viral particles. These biochemical properties strongly
suggest that it is involved in encapsidation (Zhang and
Imperiale, 2003). The lethality of this null mutation in cells
not expressing IVa2 protein could arise solely from the
failure to encapsidate genomes, but does not indicate if the
protein is also essential because of its role in the early to late
switch in transcription.
The transactivation properties of IVa2 protein have only
been observed in various kinds of reporter systems, either in
infection–transfection systems or in ectopic locations in the
viral genome. These results sometimes present discrepancies
with results found in vivo, especially in the MLP with its
functionally redundant elements. Furthermore, structure-
function studies have been limited to the use of recombinant
vectors or proteins. Therefore, we decided to study thetransactivating function of IVa2 in the correct viral context.
Genetic methods were developed to examine the phenotypes
of a set of mutations in the IVa2 ORF to clarify its various
functions.Results
Construction and analysis of mutations in the IVa2 gene
In order to study the function of IVa2 in the context of the
virus genome and life cycle, a series of mutations was
constructed including two individual nonsense mutations at
codons 6 and 86, one frame-shift mutation at codon 277, a
deletion of codon 424, and two mutations in the putative
Walker A box that changed the conserved lysine into either
alanine or arginine. The expected protein products are shown
in Fig. 1, which also shows the functional regions of the
protein identified from transfection experiments performed
with IVa2 expression vectors, and motifs deduced from the
sequence (Lutz and Kedinger, 1996; Lutz et al., 1996).
Two methods of virus construction were used to examine
the viability or phenotype of these mutations. The first
attempts were with the cotransfection method with
pPM100. Several transfections with the BstEII and BstXI
mutations either were unproductive or gave rise only to wild-
type virus. This implies either that the mutations are lethal or
that in these particular transfections, crossovers were to the
right of the IVa2 mutation (see Materials and methods).
Because these results were inconclusive, an alternative meth-
od was used to construct whole genomes containing the
mutations (see Materials and methods). Provided the genome
is constructed correctly, the failure to obtain virus is very
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recombination in the transfected cell, and the lethality of the
IVa2 mutation can be tested by marker rescue with a cotrans-
fected plasmid containing the wild-type sequence.
The results with the second system of construction show
that the BstEII and BstXI mutations cannot be recovered in
virus, but both can be corrected by marker rescue with the
wild-type sequence in pAP6 or pAP1 (Table 1, rows 1, 2).
Similarly, the mutations of the putative Walker A box were
not recovered in virus but could be corrected (Table 1, rows
3, 4). The pGenVec-BstEII, K177A, and K177R DNAs were
also viable in a 293-cell line expressing IVa2 protein (Zhang
and Imperiale, personal communication). Taken together,
these results show that the lethality of these constructs is
caused by the IVa2 mutations themselves.Table 1
Plasmids (GV) carrying the mutation/s of interest or pPM100 were
transfected into 293A cells alone or together with different rescuing
plasmids
Row Plasmidsa Transf.b Plt.c Resc.
Plas.d
Yielde Sequencef
1 GV-BstEII 2 5 none 
2 pAP6 + vGVWT
2 GV-BstXI 5 11 none 
4 pAP1 +
1 pAP6 +
3 GV-K177A 2 6 none 
2 pAP1 +
4 GV-K177R 2 6 none 
2 pAP1 +
5 GV-BstXI 2 6 pAP8 
2 pAP1 +
6 pPM100 1 2 pAP5 + #2,#8; vWT
7 GV-M75L 3 3 none + vM75L
1 pAP1 +
8 GV-M101L 1 1 none + vM101L
9 GV opal6-M75L 4 6 none 
4 pAP1 + vGVWT
1 pAP2-
M75L

1 pAP1-
M75L
+ vM75L
7 pAP2 + vOpal6
10 GV opal6-M101L 3 7 none 
3 pAP1 +
5 pAP2 + vOpal6
pAP1: Ad5 sequence 3533–5793, pAP2: pAP1 carrying the opal6
mutation, pAP6: Ad5 sequence 3533–9523, pAP5: pAP6 carrying the
opal6 mutation, pAP8: pAP6 carrying the PflMI mutation, pAP1-M75L:
pAP1 carrying the M75L mutation, pAP2-M75L: pAP1 carrying both, the
opal6 and M75L mutations. Viruses #2, #8: vIVa2#2, vIVa2#8, vGVWT:
GenVec background virus wild type in sequence, vM75L: GenVec
background virus carrying the M75L mutation, vM101L: GenVec
background virus carrying the M101L mutation, vOpal6: GenVec
background virus carrying the opal6 mutation.
a Plasmid/s transfected into 293 cells.
b Number of transfections.
c Total number of plates.
d Rescuing plasmid.
e Virus yield (F).
f Analysis of the recovered virus.The PflMI mutation results in a single deletion of valine at
position 424 in the amino acid chain. None of the experi-
ments with the pPM100 cotransfection method were infor-
mative. The PflMI mutation was not constructed into a
GenVec plasmid but a small plasmid carrying the mutation,
pAP8, was used to try to rescue the nonviable pGenVec-
BstXI (Table 1, row 5). Two different cotransfections, with
three replicates each, were all negative, although the muta-
tion in pGenVec-BstXI was rescued by pAP1. The probabil-
ities of recombination between the PflMI and the BstXI
mutations predict that 60% should inherit the former muta-
tion and 40% should be wild type. The ability to correct
pGenVec-BstXI with pAP1, which contains the same length
of leftward flanking DNA sequence, suggests that the
deletion of this single amino acid is lethal. However, as with
the pPM100 cotransfection method, a negative result is not
conclusive.
The apparent lethality of the mutations predicted to result
in truncated products and the single point mutations in the
Walker A box are consistent with the recent observations that
a pair of stop codons at positions 17 and 19 are lethal (Zhang
and Imperiale, 2003). It was therefore a surprise to find that
the opal6 mutation was viable when tested in the pPM100
cotransfection system. A single transfection was performed
(Table 1, row 6) and the yield contained a mixture of plaques
with small and large sizes. Two different small plaque
isolates, #2 and #8, and a large plaque counterpart (vWT)
were isolated. DNA sequencing showed the presence of the
opal6 mutation in the genomes of #2 and #8 and its absence
in vWT.
The phenotype of viruses containing the opal6 mutation
The surprising recovery of the opal6 mutation in viable
virus led us to examine the phenotype in some detail. The
original plaque isolates were plaque purified again and
higher titer stocks were made. A plaque assay was performed
with these stocks (Fig. 2A) and it showed uniformly small
plaques for isolates #2 and #8, except for a single large
plaque in #8, subsequently shown to contain a virus with a
tyrosine reversion of the opal stop codon.
A one-step replication cycle in A549 cells was performed
(Fig. 2B). Infections with both mutant isolates exhibited a
longer eclipse as compared with the comparable vWT
isolate, but the slopes of the exponential rise were parallel.
The final yield of cells infected with isolate #2 was fivefold
lower as compared with that of vWT-infected cells. Al-
though the yield per cell at 24 h.p.i. was about 10-fold lower
in cells infected with isolate #8 compared with #2, the final
yields were comparable. A one-step replication assay with
CsCl band-purified vWT and vIVa2#2 showed very similar
differences in eclipse and final yield (data not shown).
Because of concerns about the presence of revertants in
stocks of vIVa2#8, the following analyses were conducted
with vIVa2#2 only. Subsequent analysis of #8 will be
described later.
Fig. 2. (A) Plaque assay of the mutant isolates #2 and #8 and their wild-type counterpart. #8 shows a large plaque that contained a two point mutation of the
opal codon TGA to a tyrosine codon TAT(the original codon at position 6 was an arginine codon CGA). (B) One-step replication analysis of mutant isolates #2
and #8 compared with the WT isolate. A549 cells were infected at an MOI of 10. Plates were titrated at 3, 12, 14, 16, 18, 20, 22, 24, 48, and 68 h.p.i. for WT
and #2 and at the same time points except 12, 14, and 16 for #8. (C) Western blot analysis showing late proteins from band-purified vWT- and vIVa2-infected
cells. A polyclonal antibody raised against capsid proteins was used. Anti-actin antibody was used to determine equivalent loading. (D) Northern blot analysis
showing L5 and L4 mRNAs from vWT- and vIVa2-infected cells at 24 and 33 h.p.i. L5 probe is a PCR product that recognizes 687 nt of the fiber-specific
mRNAs and the L4 probe is a plasmid with Ad5 sequences from nucleotides 23432 to 27331, which include sequences for the three mRNAs of the L4 PolyA
group. 28S rRNA is used as loading control for the L5 and the L4 mRNAs.
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certain mutations in the promoter elements of the MLP
exhibit a marked replication deficiency. Because IVa2 is a
known transcription factor acting at the MLP, the deficient
replication could be caused by lowered RNA expression and
thus, lower accumulation of late proteins. After checking that
DNA accumulation was not affected (data not shown), the
RNA and protein profiles were examined. A549 cells were
infected with vIVa2#2 and vWT and harvested at intervals
postinfection. The differences in late protein accumulation,
examined by Western blotting (Fig. 2C), were not as great as
the reduction in yields might have predicted. This could be
due to a defect in encapsidation that contributes to the
reduction in yield or it could be similar to the phenomenon
already seen in virus containing mutations in the MLP
(Fessler and Young, 1998). Accumulations of late L4 and
L5 mRNAs at 24 and 33 h postinfection (Fig. 2D) were
similar in cells infected with vIVa2#2 and vWT.
These results show that the deficiencies in accumulation
of both late proteins and mRNAs are minor in cells infected
with vIVa2#2. Because full-length IVa2 protein is essential
by others and is confirmed by the results with the truncation
mutations above, it was possible that the opal6 mutation,predicted to make a truncation of only five amino acids,
could allow expression of small amounts of the full-length
protein. This possibility therefore had to be examined.
Isolate vIVa2#2-infected cells produce a smaller form of
IVa2 protein and a larger and more abundant mRNA
Cells were infected with vWT or vIVa2#2 and whole cell
or nuclear extracts were analyzed using several different
antibodies directed against IVa2 protein (Fig. 3). Initial
results with an antibody recognizing an N-terminal epitope
did not detect IVa2 protein in vIVa2#2-infected cells (Fig.
3A). However, two different antibodies prepared against full-
length IVa2 protein, detected a smaller form off40 kDa in
cells infected with vIVa2#2 (Figs. 3B, C and 8C), vIVa2#8
(Fig. 3C), and wild-type viruses (Ad5 in Fig. 3B and more
faintly in vWT in Fig. 3C and GVWT in Fig. 8C). This
smaller form could be a degradation product, a product of
initiation of translation downstream of the stop codon, or a
specific isoform encoded by a differentially spliced mRNA.
To test the last possibility, IVa2 mRNA was examined.
HEK 293 cells were infected with vWT and vIVa2#2 and
harvested at 23 h postinfection. Unexpectedly, vIVa2-
Fig. 3. (A) IVa2 protein from whole cell extracts of vWT- or vIVa2#2-infected cells detected by anti-IVa2 N-terminal-specific mouse serum. (B) IVa2 protein
from whole cell extracts of Ad5- or vIVa2#2-infected cells or cells transfected with a IVa2 expressing vector (Vr) detected by polyclonal anti-IVa2 mouse
serum. (C) IVa2 protein from nuclear extracts of vWT-, vIVa2#2-, or newly plaque-purified vIVa2#8-infected cells or uninfected control cells detected by a
rabbit polyclonal antibody directed against GST-IVa2. (There is a spillover in the last lane from overloading with WT extract in the adjacent well).
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molecular weight larger than that present in vWT-infected
cells and also present in greater quantities (Fig. 4A). In order
to identify this new species of IVa2 mRNA, 5V RACE was
performed and two products were detected in the RNA of
cells infected with isolate #2 (Fig. 4B). One was the same
size as WT and the other one was about 100 nucleotides
larger. This larger band was isolated and sequenced. The
sequence corresponds to a cDNA derived from the major late
transcription unit tripartite leader joined to the 5V UTR of 23
K, which is in turn attached to the 5V truncated second exon
of IVa2 (Fig. 4C). The first AUG encountered in the resulting
mRNA is the codon for Met75 in the wild-type IVa2 mRNA.
If a protein were to be initiated there, it would have a
molecular weight of about f40 kDa.
Determining the origin of the hybrid mRNA species
Although trans-splicing between adenovirus and cellu-
lar RNA species has been reported (Kikumori et al.,Fig. 4. (A) Northern blot analysis of IVa2 RNA. RNA from infected 293 cells analy
site at nt 5788). (B) 5V RACE of total RNA from infected cells using oAP16 for
Diagram of the hybrid IVa2 RNA showing the position of the primers used. M7
tripartite leader and the UTR of 23 K is 101 nucleotides larger than the IVa2 me2002), the hybrid 23K/IVa2 mRNA sequence exhibited
no obvious splice donor and acceptor sites surrounding
the junction site. Alternatively, the mRNA could be
derived by transcription from a hybrid DNA of the same
sequence. In order to test this, intracellular viral DNA and
RNA from vWT- and vIVa2#2-infected cells was ampli-
fied with a primer specific for 23 K and another for IVa2.
Only vIVa2-infected cells showed a product of the
expected size and sequence for both mRNA (Fig. 5A)
and DNA (Fig. 5B). This hybrid DNA was not found in
cells infected with the original isolate of #2 but arose in
the next passage (Fig. 5C). Southern analysis of DNA
from vIVa2-infected cells (Fig. 6A) and PCR with differ-
ent primers (data not shown) showed that the vIVa2#2
stock contains a piece of DNA carrying the 23K-IVa2
hybrid construct. This hybrid DNA is of about 26 kb and
contains two left ends as shown in the diagram (Fig. 6B).
The hybrid mRNA transcribed from this hybrid DNA
could be translated into a 40 kDa protein using the
tripartite leader for efficient translation.zed with plasmid pAP1D (Ad5 sequences from PflMI site at nt 4172 to XhoI
cDNA synthesis and either oAP15 or oAP14 as the amplifier primer. (C)
5 of IVa2 is the first methionine codon found in the hybrid sequence. The
ssage from the initiation to nucleotide 5340.
Fig. 5. RT-PCR (A) or PCR (B and C) with a 23K-specific primer and a IVa2-specific primer. M: molecular weight marker Ø174 HaeIII digest. P1, P2, and P3:
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DE1 and DE2 elements of the MLP
Because vIVa2#2 is viable, while other viruses with
mutations leading to different truncations of the IVa2 protein
are not, the inference is that the 40 kDa species is able to carry
out the function/s of IVa2. IVa2 protein has been shown to
bind to the packaging sequence (Zhang and Imperiale, 2000)
and to the MLP DE1/2 (Tribouley et al., 1994). To test the
ability of the smaller IVa2 species to bind to these elements,
electrophoretic mobility shift assays were carried out (Fig. 7).
Nuclear extracts from cells infected with vIVa2#2, and a
duplex spanning the AI and AII repeats of the packaging
passage 1, 2, and 3 of isolate #2.Fig. 6. (A) Southern blot analysis of the hybrid DNA. VWT- and vIVa2-infected ce
molecular weight marker. (B) Diagram of WT and hybrid DNA.sequence show a faster migrating band as compared with
extracts from Ad5 wild-type-infected cells, consistent with
binding of the 40 kDa form (Fig. 7A). Assaying the binding
of 40 kDa to the MLP DE1 and DE2 elements showed
analogous results. An extract from vWT-infected cells exhib-
its a specific band (Fig. 7B, lane 2), which is reduced by
competition with a nonlabeled probe (Fig. 7B, lanes 3 and 4)
but is not competed by a mutated DE1/DE2 duplex oligonu-
cleotide (Fig. 7B, lane 5). In contrast, an extract from
vIVa2#2-infected cells shows a faster migrating band. As-
suming that charge and conformation of the 40 kDa isoform is
the same as that of IVa2, the faster migrating band would be
consistent with binding of a smaller form of protein IVa2 (Fig.lls Hirt DNA probed with the BstXI–BstEII fragment of plasmid pAP1. M:
Fig. 7. (A) Electrophoretic mobility assay (EMSA) of IVa2 and packaging sequence. Nuclear extracts (NE) of infected 293 cells and a AI– II packaging repeat
probe. (B) EMSA of IVa2 and a probe spanning the DE1/2 elements. NE of uninfected (1), vWT-infected (2–5), or vIVa2-infected (6–10) A549 cells.
Competition by a nonlabeled DE1/2 probe (3, 4, 7, 8) and by a mutated nonlabeled DE1/2 probe (5, 9, 10).
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competition with the nonlabeled competitor (Fig. 7B, lanes
7 and 8), but is not reduced by a mutant probe (Fig. 7B, lanes
9 and 10). Supershift analysis to prove the identity of the
faster migrating band as a complex containing a IVa2 deriv-
ative could not be performed due to lack of available reagents.
However, the complex formation with a duplex containing
DE1/2 that previously had been proved to bind only com-
plexes that contained IVa2 (Tribouley et al., 1994) and the
specific competition by a wild type probe but not by a
mutated form strongly suggest that the complex does in fact
contain some form of IVa2. These results are consistent with
the idea that the smaller 40 kDa protein is capable of
performing the known binding functions of IVa2 protein,
and suggests that this is sufficient for virus viability.
Cells infected with isolate vIVa2#8 also show a 40 kDa
protein, but no evidence for a hybrid DNA
The 40 kDa protein detected in cells infected with
vIVa2#2 may be sufficient for almost normal levels of late
transcription and protein production and be able to function
in encapsidation. Furthermore, the expression of this smaller
species might be dependent on the tripartite leader, which is
used for very efficient translation late in infection (Logan and
Shenk, 1984). As mentioned earlier, the first passage of the
original isolate #2 did not contain this hybrid DNA, and nor
did isolate #8 (data not shown). It was also shown that the
hybrid DNA could be eliminated from stocks of vIVa2#2 by
further plaque-purification and the plaques obtained are of
same size as those of vIVa2#8 (Fig. 2A). This suggests that
the only difference between these isolates was the hybrid
DNA and it raises the question of the mechanism underlying
the viability of the isolates lacking the hybrid DNA.To eliminate the revertants present in stocks of vIVa2#8,
isolate #8 was plaque purified again and new stocks were
grown. The virus DNA was sequenced and no reversion of
the opal6 mutation was detected. No hybrid DNA was
detected by Southern analysis. Northern blots and 5V RACE
analysis revealed IVa2 mRNA of the size and sequence
expected for transcription of the opal6 mutation from the
IVa2 promoter (data not shown).
In order to see if this virus was making protein IVa2, a
Western blot was performed with nuclear extracts from cells
infected with the newly plaque-purified vIVa2#8 (Fig. 3C).
Extracts from cells infected with wild-type viruses show a
species atf55 kDa and also a 40 kDa species faintly seen in
Fig. 3C but better appreciated in Figs. 3B and 8C, although
extracts from cells infected with isolates #2 and #8 show
only the 40 kDa (Fig. 3C). EMSA experiments performed
with nuclear extracts from cells infected with isolate #8 show
that they too contain species capable of retarding the duplex
oligonucleotide to a position comparable to that seen in
extracts from cells infected with isolate #2 (data not shown).
Thus, it seems that the level of expression of this 40 K
form in isolate #8 is also sufficient for viability.
Identifying the initiating methionine of the 40 kDa species
In the IVa2 mRNA, the sequence surrounding the first
AUG does not conform to the Kozak consensus sequence
(Fig. 8A), but neither do the sequences surrounding the AUG
for methionine 75, which would give a product of 41 kDa,
and methionine 101, which would give a product of 38 kDa,
if used as the initiating methionine. Methionine 75 is not well
conserved in the Mastadenoviridae, although methionine
101 is conserved in all except MAV1 (Fig. 8B). In order to
find out which of the two is used, codons 75 and 101 were
Fig. 8. (A) IVa2 AUGs coding for M1, M75, and M101 are not in a Kozak consensus sequence. (B) Alignment of IVa2 from amino acid 58 to 113. h: human;
s: simian; c: canine; p: porcine; b: bovine; m: murine; t: tree shrew. (C) Western blot analysis using rabbit polyclonal anti-IVa2 antibody of NE from infected
A549 cells. GVWT: WT virus in a GenVec background; vM75L: virus carrying the M75L mutation: vM101L: virus carrying the M101L mutation; UIC:
uninfected cells.
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and the phenotype of the virus studied. A single transfection
with the GenVec plasmid carrying either the M75L or the
M101L mutation yielded virus (Table 1, rows 7, 8) that
replicated at WT levels (data not shown). However, trans-
fections with a full-length plasmid carrying both the opal6
mutation and either the M75L or the M101L mutations
yielded no virus (Table 1, rows 9, 10). The lethality could
be corrected when the double mutation-containing plasmids
were cotransfected either with a plasmid carrying the wild-
type sequence or with a plasmid carrying opal6. In the latter
case, the resulting virus contained the opal6 mutation but in a
different genetic background to the original vIVa2 isolates.
As with vIVa2, these new derivatives had a small plaque
phenotype and replicated less well. The lethality of both
double mutations suggests that both methionines are impor-
tant to function, but the results do not distinguish which one
is used as the initiating codon.
To analyze this further, we performed Western blots with
nuclear extracts from vM75L- and vM101L-infected cells,
and compared them to that from vIVa2-infected cells (Fig.
8C). The 40 kDa species is present in both the vIVa2- and
vM101L-infected extracts but not in the vM75L-infected
extract. This suggests that codon 75 is the one used as the
initiating methionine for the 40 kDa protein form.Discussion
A recent report showed that an adenoviral genome with
stop codons at positions 17 and 19 in the ORF for IVa2 was
not viable unless complemented in trans by expression of
IVa2 protein (Zhang and Imperiale, 2003). This result showsthat IVa2 protein is essential for viral replication. It is now
known that IVa2 protein plays a role in both encapsidation
(Zhang et al., 2001) and in control of late transcription from
the MLP (Tribouley et al., 1994); thus, in principle, either or
both of these functions of IVa2 might be essential to viral
replication. Despite these advances, however, structure-
function studies have been done only in transient transfec-
tion assays, but never in the context of the virus. Because
results obtained with transfection assays may not reflect
those obtained in virus, we attempted to create a series of
mutations in the IVa2 ORF (Fig. 1) and used a variety of
methods to reconstruct them into a full-length viral genome.
Two mutations leading to truncation proteins and two
independent mutations in the Walker A box motif were not
recovered in virus, suggesting that they are lethal. Their
lethality could be attributed to the IVa2 mutations because
it could be reversed by recombination with a small plasmid
containing the wild-type sequence of IVa2, and three of
them were tested in 293-IVa2 cells and virus could be
recovered (Zhang and Imperiale, personal communication).
Although the results with the PflMI mutation, in which a
single amino acid (V424) is deleted, were not conclusive, it
was not recovered in virus. Although this result might seem
surprising, Val424 is part of the hydrophobic side of a
putative amphipathic a-helix (this hydrophobic amino acid
is also conserved in Mastadenoviridae), and is part of the
C-terminal region of the protein essential for DNA binding
(Lutz and Kedinger, 1996). The lethality of the mutations
in the putative Walker A box suggests that this motif
probably does function as a nucleotide triphosphatase and
that this function is essential. This is under active investi-
gation (W. Zhang and M. Imperiale). Taken together with
the earlier results of Zhang and Imperiale, these results
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replication.
Given the results above, it was surprising that a nonsense
mutation at codon 6 was recovered in virus, although it
clearly had a deficient replication cycle as compared to wild
type (Fig. 2). It was therefore of interest to analyze the
phenotype of the vIVa2 viruses in some detail. Western
analysis showed that proteins from cells infected with iso-
lates vIVa2#2 and #8 (Figs. 3B, C) contained IVa2 species of
about 40 kDa. Northern analysis showed that mRNA from
cells infected with isolate vIVa2#2 contained an extra, larger,
IVa2 mRNA (Fig. 4A), which on analysis of 5V RACE
products was shown to consist of the MLTU tripartite leader,
spliced to part of the 5V noncoding region of the 23 kDa
transcript, joined to most of the IVa2 second exon (Figs. 4B,
C). The origin of this hybrid mRNA was shown to be a
corresponding hybrid genome present in the viral stock
(Figs. 5 and 6). In the hybrid mRNA, the first AUG
encountered encodes M75, and if translation initiates there,
would allow the production of a 40 kDa version of the IVa2
protein. Translation at late times of infection would be
expected to be efficient because it is directed by the tripartite
leader.
However, cells infected with isolate #8 did not contain an
extra IVa2 mRNA but only one of wild-type length and
containing the opal6 mutation. In this case, as in that of the
vWT, the 40 kDa isoform could be produced by initiating at a
downstream AUG either by ribosome shunting or by leaky
scanning. Shunting is possible because in transfections with
an artificial construct, the IVa2 5V noncoding region (NCR)
directed ribosome shunting, although translation was at only
30% the level of that directed by the tripartite leader in a
similar construct (Yueh and Schneider, 2000). Leaky scan-
ning could also occur because the first AUG is not in a good
Kozak consensus sequence (Fig. 8A) and the ribosome might
bypass the first AUG and scan until the second one which
usually encodes M75.
The production of the 40 kDa species by either mecha-
nism might be sufficient for viability. However, we cannot
rule out the possibility of read-through of the stop codon at a
low level, such that a full-length 55 K IVa2 protein is made
in quantities undetected by the antibodies used in the
Western blot analyses (Figs. 3B, C), but sufficient for
viability. The efficiency of termination at a stop codon
depends on the context of the neighboring nucleotides. An
adenine in the 1 position from the stop codon in mamma-
lian cells, at least in the amber stop codon, has been
associated with the highest read-through levels (Cassan
and Rousset, 2001). It is also known that strong termination
codons have an A or G at +4, although weaker ones have U
or C (Sogaard et al., 1999). In the case of the opal codon 6,
it does not have a ‘‘weak’’ A at 1 position (underlined) but
does have a ‘‘strong’’ A at +4 (in bold), which makes it
likely to be a strong stop codon (GGG UGA AGA). Thus,
we consider it unlikely that read-through is the mechanism
underlying the viability of opal6.If the stop codon at codon 6 is bypassed, this raises the
question of which downstream methionine is used for
initiation. The alignment shown in Fig. 8B reveals that
M75 is not conserved among Mastadenoviridae but M101
is almost invariant. We reasoned that mutating either M75
or M101 would reveal which one was used to produce the
40 kDa species. Virus genomes containing M75L or
M101L were recovered easily and replicated as well as
wild type (data not shown). However, genomes containing
either the M75L or M101L mutations together with the
opal6 mutation were inviable. Thus, the genetic analysis
did not reveal which methionine codon was used in the
opal6 context. Western blots showed that vM75L-infected
cells do not produce the 40 kDa species although those
infected by vM101L do (Fig. 8C), implying that the M75
codon is the one used for initiation of the 40 kDa. An
opal6-M75L virus would not be able to make the 40 kDa
protein and therefore would be lethal. The lethality of the
BstEII mutation would also be consistent with M75 as the
downstream initiating methionine because it creates an opal
codon at position 86. In the case of opal6-M101L, as
mentioned above, M101 is conserved suggesting that it
must have some important function. In the context of the
full-length IVa2 protein, a change to leucine, another
nonpolar hydrophobic amino acid, is functional but in the
context of the 40 kDa, it might abolish function, rendering
the virus nonviable.
A 40 kDa form of IVa2 is also present in cells infected by
vWT (Figs. 3C and 8C), although at lower levels than in
those infected by the opal 6-containing viruses. Could this
species have a biological role in the wild-type infection? The
IVa2 55 kDa protein binds to the MLP downstream elements
DE1 and DE2a as a 55/40 kDa ‘‘DEF-A’’ heterodimer
(Tribouley et al., 1994). The smaller species could not be
purified and was thus not identified (Tribouley et al., 1994).
DEF-A was present only in infected cells, making it likely
that the 40 kDa is a viral protein or a virus-induced protein
(Lutz et al., 1996). Significantly, the 40 kDa species was not
observed in cells transfected with an expression vector that
contained only the IVa2 ORF (and see Fig. 3B), and the
stimulatory effect of IVa2 expression upon an MLP reporter
plasmid occurred only late in cells infected with wild type
virus (Tribouley et al., 1994). These observations are con-
sistent not only with the 40 kDa species being the partner of
full-length IVa2 protein in DEF-A but also being necessary
for transactivation. Furthermore, if the unidentified species is
an isoform of IVa2 protein, production of this species might
occur only late in infection via a shunting mechanism. This
would not occur if the mRNA is derived from a cloned ORF
introduced to the cell by transfection. The 40 kDa form that
we have observed (Figs. 3B, C and 8C) could be the same as
the partner of IVa2 55 kDa in the DEF-A heterodimers
described earlier.
Assuming that read-through of the stop codon is very
infrequent, the implication would be that the 40 kDa species
observed in cells infected with vIVa2 isolates #2 and #8 is
A. Pardo-Mateos, C.S.H. Young / Virology 324 (2004) 151–164160sufficient for viability and must be able to perform the
functions of IVa2. In agreement with this idea, it was found
to be capable of binding the packaging sequence AI–II
repeats (Fig. 7A), and thus can mediate encapsidation. It
remains an open question as to whether or not binding of a 40
kDa species occurs, perhaps as a heterodimer, in wild-type-
infected cells. The 40 kDa species can also bind the down-
stream elements of the MLP (Fig. 7B). This result refines the
coordinates of the N-terminal DNA binding domain de-
scribed earlier to lie between amino acids 50 and 100 (Lutz
and Kedinger, 1996). When high levels of the 40 kDa species
are produced, as in cells infected with isolate #2, almost
normal levels of late mRNAs and proteins are observed
(Figs. 2D, C). This suggests that transcription from the MLP
is close to normal even in the absence of the full-length 55
kDa species. It is more difficult to assess if the binding of 40
kDa is functional, because of the redundancy of the tran-
scription factor binding sites in the MLP (Reach et al., 1991).
Even if the 40 kDa binding is nonfunctional, other factors
such as USF and CP1 binding to the UPE and CAAT boxes,
respectively, might be sufficient for high levels of transcrip-
tion from the MLP. However, it is noted that late products are
more abundant in cells infected with isolate #2 than in those
infected with #8 (data not shown), consistent with a positive
effect of the 40 kDa species.
The null mutant with two stop mutations at codons 17
and 19, described recently (Zhang and Imperiale, 2003),
could only grow in complementing 293-IVa2 cells. How-
ever, 293 cells infected with this mutant exhibited a small
amount of a protein that migrated faster than the IVa2
protein. It is not clear if it has the same molecular weight
as the IVa2 derivative exhibited in cells infected with
isolates #2 and #8, but if it is the same, perhaps the amounts
produced are insufficient for viability. The shunting mech-
anism directed by the IVa2 5V NCR or the leaky scanning
could be obstructed by those two codons if they change the
mRNA secondary structure in a manner different to the
opal6 mutation. Alternatively Nonsense-Mediated Decay
might be more efficient at degrading the mRNA in the
double mutant mRNA.
The unexpected discovery that the opal6 mutation is
viable has led to testable hypotheses as to the role(s) of
the smaller 40 kDa species of the essential IVa2 protein in
both encapsidation and late transcription. In conjunction
with the recently developed cell line expressing IVa2 in
trans, it should now be possible to examine each role in
detail. For example, a set of mutations in the MLP coupled
with the opal6 mutation could address the question of the
role of the 40 kDa in trans-activation of the MLP and
possible protein–protein interactions at the promoter. Sim-
ilarly, the role of the 55 kDa protein in transcription, in the
absence of the 40 kDa species, is now easily addressed
using the M75L mutation coupled to mutations in the MLP.
The set of mutations described here, expressing either 55 or
40 kDa alone, may also prove useful in detailed analysis of
encapsidation.Materials and methods
Mutant virus construction
Two different methods were used to create virus. The first
system involved recombination in 293 cells among two
plasmids, a shuttle plasmid carrying the mutation and
pPM100. pPM100 was derived in a series of steps from
pFG154 (Lippe and Graham, 1989), virus LLX1 (Brunet et
al., 1987), and pDQ1 (Quan and Young, unpublished). It
contains the adenovirus genome sequence with the left and
right ends juxtaposed, a lethal 8 bp insertion/deletion muta-
tion in the DNA polymerase gene at nt 5990 and the plasmid
vector sequence (pMX2) substituting for most of the E3
region. Viable virus will only be produced if recombination
removes the lethal DNA polymerase mutation. If the IVa2
mutation of interest is not lethal, two recombinant products
can be obtained, depending on the position of the crossover.
Recombination to the left of the IVa2 mutation will yield a
mutant virus genome and to the right, a fully wild-type
genome. Plasmids were cotransfected into 293A cells using
the calcium phosphate precipitation method (Graham and
van der Eb, 1973), and cells were observed for several days
until cytopathic effect (cpe) was detected. If no cpe was
observed on the transfection plates, two more rounds of
infection were performed.
The second method involved a system developed by
GenVec Inc. (McVey et al., 2002), based on a system first
developed for adenovirus by Chartier et al. (1996) in which
full-length adenovirus genomes are produced by recombina-
tion between two linearized plasmids in recA+ recBCD
sbcBC E. coli. The plasmid pAdE1(BN)E3(10) contains
the whole adenovirus sequence, except the E3 region, with
the kanamycin-resistant plasmid vector sequence (pACYC
174) inserted between the two ends of the virus genome. The
BN cassette, which replaces the E1 region, produces a
bacteriocin when the promoter is induced by IPTG. Plasmid
pAdE1(BN)E3(10) was linearized by SwaI, which cleaves in
the BN cassette, and dephosphorylated. It was cotransformed
with linearized shuttle plasmid, carrying the mutations of
interest, into competent BJIq E. coli. The transformed cells
were induced by IPTG under kanamycin selection. Only
bacteria carrying plasmids in which recombination has taken
place, excising the BN cassette, survive. Bacterial colonies
arising on the selection plates were inoculated into 5ml liquid
cultures under kanamycin selection, and the plasmid DNA
was extracted using Qiagen (Valencia, CA) mini columns.
The yields of DNA were usually insufficient for simple
analysis and so the DNA preparations were used to transform
competent HB101 E. coli. Individual transformations that
yielded high numbers of colonies usually contained deleted
plasmids, and those samples were discarded. Samples with
fewer colonies were screened and those plasmids carrying the
mutations of interest were identified. The mutation-contain-
ing plasmids were amplified, digested with PacI, and used to
transfect 293A cells. A marker rescue assay with a plasmid
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formed routinely in parallel with this transfection. If virus was
only produced from the marker rescue plates, it strongly
suggests that the IVa2 mutation is lethal. As with the first
method, potential transfection yields were passaged twomore
times.
After plaque purification of the individual mutant viruses
obtained by either construction method, the region of the
viral genome immediately surrounding the mutation was
sequenced. All sequences were as expected.
Mutagenesis
The shuttle plasmids used for the construction of mutant
viruses and for marker rescue were as follows:
 pMR2 (Reach et al., 1990) contains Ad5 sequences from
nt 1 to nt 9523 bounded at the left-hand and right-hand
ends by the EcoRI and BamHI sites of pBR322,
respectively, with a mutated HindIII site at bp2804, a
mutated XhoI site at nt 8254, and a 6 nt insert at nt 6079
creating an EcoRI site.
 pAP1 is a clone of the Ad5 AflII to XhoI fragment in
pSL180 (Brosius, 1989) and contains adenovirus
sequences from nt 3533 to nt 5793.
 pAP6, is a clone of the pMR2 XhoI to BamHI fragment
in pAP1, and extends Ad5 sequences up to nt 9523.
Individual mutations were created as indicated in the
following sections.
Mutation opal6
The mutation was designed so that there was no change to
the amino acid sequence of the DNA polymerase, encoded on
the same strand but in a different reading frame to IVa2. A G
to a transition at nucleotide 5425 in the Ad5 sequence creates
an opal codon at position 6 of the IVa2 ORF. This is the first
codon that can be changed to a stop codon because the first
four codons are in the first exon and are in frame with the
DNA polymerase sequence. The fifth codon is created by
splicing and then the IVa2 ORF is in a different frame. The
mutation was created by PCR using the primers oAP1
5VGAAGCGC TGCCGGTCTTC aCCCTGCGCGTCG-
GCC3 V and oAP2 5 VGCGACCGCGGACATGTA-
CAGAGCTCGAG GACAGG3V and pAP1 DNA as a
template. The PCR product was cut with BbsI and XhoI
(underlined in oAP1 and 2, respectively) and recloned into
pAP1, creating the plasmid pAP2. Analogous to the pAP6
construction, the XhoI to BamHI fragment was cloned into
pAP2 giving pAP5, a plasmid with Ad5 sequences from
bp3533 to bp9523. pAP5 was cotransfected into 293 cells
with pM100.
Mutation BstEII
The following mutations (BstXI, BstEII, and PflMI) were
made using restriction sites that are unique to IVa2 andplasmid pAP1. The BstEII restriction site at nt 5187 was
filled in to create an opal codon at position 86. The DNA
polymerase ORF terminates within codon 81 of IVa2; thus, a
change in IVa2 thereafter will not affect the DNA polymer-
ase. The AflII to XhoI fragment of pAP1-BstEII was cloned
into pMR2, and this plasmid (pMR2-BstEII) was cotrans-
fected with pM100 on 293A cells. The BstEII mutation was
also placed in a full-length genomic plasmid (pGenVec-
BstEII) using the GenVec reconstruction method with
pMR2-BstEII as the shuttle plasmid.
Mutation BstXI
The BstXI restriction site at Ad5 nt 4611 in pAP1 was
resected to create a +1 frameshift at codon 277 leading to a
stop codon at position 320. The resulting plasmid pAP1-
BstXI was used to create pAP7 in which adenovirus sequen-
ces extend to nt 9523. Transfections were conducted with
pPM100 and pAP7. A pMR2 derivative was also created and
this was used to make pGenVec-BstXI.
Mutation PflMI
The PflMI restriction site at Ad5 nucleotide 4172 in pAP1
was resected resulting in a deletion of the codon for Val424.
Plasmid pAP1 was grown on a dcm strain to allow cleavage
with PflMI, and the ends were resected and then ligated back
together (pAP1-PflMI). This was extended to nt 9523 to
create pAP8. This plasmid was cotransfected with pM100.
Mutations K177A and K177R
Codon 177 was mutated from AAG (K) to gcG (A) in a
double PCR reaction using pAP1 DNA as a template, a
flanking upstream primer (oAP16: 5VCGTCCATAAT
GATGGCAATGGGCCCACGGG3V) with a mutagenic
primer (oAP17: 5 VCACCGGCT GCGGTgcGTCG-
CAGCTGCTCAG 3V), and a flanking downstream primer
(oAP19: 5V G TAGAGCAGGTGACCGAGCTGTGGGA-
CCGC3V) with the complementary mutagenic primer
(oAP18: 5VCTGAGCAGCTGCGACgcACCGCAGCC-
GGTG3V). Both PCR products were used in conjunction in
a second PCR reaction with the flanking primers. The final
PCR product was cloned back into pAP1 using the BstXI
and BstEII sites (underlined in oAP16 and oAP19, respec-
tively) and then into pMR2. This was used to create
pGenVec-K177A.
A similar strategy was used to mutate AAG (K) to Aga (R)
using mutagenic primers oAP39 (5VCACCGGCTGCG-
GTAgaTCtCAGCTGCTCAG3V) and oAP40 (5VCT GAG-
CAGCTGaGAtcTACCGCAGCCGGTG3V). The mutagenic
oligonucleotides also contain mutations (lower case only)
that create a BglII site while maintaining the amino acid
change. The PCR product was cloned as for the K to A
mutation to create pGenVec-K177R.
Mutations M75L, opal6-M75L, M101L, and opal6-M101L
A T to g transversion at nucleotide 5218 in the Ad5
sequence changes methionine 75 to leucine and the same T
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to leucine. The mutations were made by PCR using pAP1
DNA as a template. For M75L, primers oAP20 (5VTC-
GGTCACC TGCTCTACGGCATCTCGATCCAG-
CAgATCTCC 3V) and oAP21 (5VGACGCGCAGGGC-
GAAGACCG GCAGCGCTTCAG3V) were used. For
M101L, primers oAP24 (5VCAGGTGACCGAGCTGTGG-
GACCGCCTGGAACTGCTTGGTCAAACGCTCAAAA-
GCcTGC3’) and oAP16 (5VCGT-CCATAATGATGG
CAA TGGGCCCACGGG3V) were used. The PCR prod-
ucts were cut with BstEII and BbsI (underlined in oAP20
and oAP21, respectively) for the M75L mutation and with
BstEII and BstXI (underlined in oAP24 and oAP16,
respectively) for the M101L mutation and cloned back
into pAP1. The HindIII to BbsI fragment of pAP1-M75L
and of pAP1-M101L was cloned into pAP2 (opal6). The
same series of cloning steps as for K/A and K/R was used
to create a set of pGenVec full-length plasmids.
Cell culture and viral infection methods
All analyses were conducted with monolayer cultures
of either A549 human lung carcinoma cells or 293A
cells, a subclone of HEK 293 cells (Quantum Biotech-
nologies Inc., Montreal, PQ). A549 and 293A cells were
grown in Dulbecco’s modification of Eagle’s medium
with 10% ‘‘defined/supplemented’’ bovine calf serum or
FetalClone II, respectively (HyClone, Logan, UT), and
antibiotics. Cells to be infected were plated in 35-mm
culture dishes 2 days before the addition of virus and
were confluent when used. Cells were infected at the
multiplicities of infection (MOI) indicated for the indi-
vidual experiments.
Measurement of viral one step replication cycles
Human A549 cells in 35-mm diameter dishes were
infected at a multiplicity of infection (MOI) of 10 fluorescent
focus units (FFU) per cell. After adsorption, the cells were
incubated at 37 jC, and at intervals, dishes were removed
from the incubator and the entire contents were frozen.
Following two more cycles of freezing and thawing, the
samples were titrated by fluorescent focus assay (Philipson,
1961) and the total numbers of viruses per cell were
calculated.
Southern blot analysis
DNA was prepared from infected cells using a modi-
fication (Volkert and Young, 1983) of the Hirt method
(Hirt, 1967). After the DNA was digested with the
appropriate enzymes, the samples were subjected to elec-
trophoresis at 70 V in a 1% agarose gel. The gel was
denatured in a 0.5 M NaOH, 1.5 M NaCl solution, and
then incubated in a neutralizing solution (1.5 M NaCl, 0.5
M Tris–HCl, pH 7.2, 0.01 M Na2EDTA). DNA wastransferred via capillary action overnight to a nylon mem-
brane (NytranN, Schleicher and Schuell, Keene, NH) in 20
SSC. The filter was exposed to UV to cross-link the DNA to
the membrane. Filters were blocked in prehybridization
solution (5 SSPE, 5 Denhardt’s solution, 200 Ag/ml
ssDNA 50% formamide [v/v]) for 6 h at 50 jC. Samples
were then hybridized to 200 ng of labeled probe overnight.
Probes were labeled by random hexamer-primed incorpora-
tion using biotinylated-dATP in a dNTP mix using the
NEBlot Phototope kit (New England BioLabs, Beverly,
MA). Filters were washed twice with 2 SSC 0.5% SDS,
and then twice with 0.1 SSC 0.1% SDS before develop-
ment with the Phototope-Star Detection reagents (New
England BioLabs). The filter was exposed to film for up to
5 min.
Northern blot analysis
A549 cells in 35-mm dishes were infected at MOI 5 and
harvested at the indicated times postinfection. Cells were
pelleted and washed in PBS. Total infected cell RNA was
isolated with Triazol Reagent (Invitrogen life technologies,
Carlsbad, CA). RNA was denatured at 70 jC for 2 min in
RNA loading buffer-denaturation solution (0.8 ml 10
MOPS, 0.4 ml 80% glycerol, 0.4 ml bromophenol blue,
1.4 ml 37% formaldehyde, 4 ml formamide). Samples were
loaded onto a formaldehyde-agarose gel (1% agarose, 1.8%
Formaldehyde (37% W/W), 1 MOPS) and subjected to
electrophoresis for 4 h at 60 V in a 1 MOPS buffer. RNA
was transferred via capillary action overnight to a nylon
membrane (NytranN, Schleicher and Schuell) in 20 SSC.
Filters were processed essentially as for the Southern
analysis. Biotinylated probes were made either by PCR
from viral DNA isolated by the Hirt method, in analysis
of viral late RNAs or using a plasmid carrying the necessary
adenovirus sequences in IVa2 RNA.
Western blot analysis
A549 cells in 35-mm dishes were infected at MOI 5 and
harvested at the indicated times postinfection. Cells were
pelleted and washed in PBS. Total protein was isolated by
resuspending the pellet in RIPA buffer: 1 PBS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS, and one tablet
of protease inhibitors (Complete Mini, Roche Diagnostics
GmbH, Mannheim, Germany) per 50 ml buffer. Protein
samples were mixed with an equal amount of 2 loading
buffer (1.125 M Tris–HCl, pH 6.7, 4% SDS, 20% [v/v]
glycerol, 0.2 M DTT, 0.02% bromophenol blue) and boiled
for 2 min before loading on precast polyacrylamide 10%
Tris–Glycine gels (PAGEr Gold, Cambrex Bio Science
Rockland Inc., Rockland, ME). Samples were subjected
to electrophoresis for 3 h at 60 V until the BPB dye front
reached the bottom of the separating gel. The gel was then
equilibrated in transfer buffer (48 mM Tris base, 39 mM
glycine, 5% methanol, 3.75% SDS). Proteins were trans-
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ter onto a nitrocellulose filter (Protran, Schleicher and
Schuell). The filter was blocked overnight in 5% nonfat
dry milk in PBS. Primary antibody was diluted 1:2000 in
5% nonfat dry milk in PBS for late proteins and 1:1000 for
anti-IVa2 mouse serum (Zhang and Imperiale) or 1:500 for
anti-IVa2 rabbit serum (Ostapchuk and Hearing). Filters
were incubated for 90 min at room temperature in 20 ml of
diluted antibody, and then washed twice with PBS-T (PBS,
0.05% Tween). Horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibodies (Amersham Biosciences,
Amersham, UK) were used as secondary antibody. Filters
were incubated for 90 min in 20 ml of a 1:1000 dilution of
this antibody in 5% nonfat dry milk in PBS. Filters were
developed by chemiluminescence with the Western blotting
luminol reagent (Santa Cruz Biotechnology, Santa Cruz,
CA) and exposed to film for up to 1V for the viral late
proteins and up to 5V for protein IVa2. For loading control,
a variety of primary antibodies against actin were
employed.
Rapid amplification of 5V cDNA ends
Rapid Amplification of cDNA Ends (RACE) was per-
formed with the a 5V/3V RACE Kit (Roche Diagnostics
GmbH) using total RNA from infected cells. cDNA was
synthesized by AMV reverse transcriptase using a specific
IVa2 antisense primer and purified cDNA was tailed with
dATP and terminal deoxynucleotide transferase (TdT). The
tailed cDNA was amplified by PCR using the Oligo dT-
anchor primer and a nested specific IVa2 antisense primer.
The PCR products were purified using the High Pure PCR
Product Purification Kit (Roche Diagnostics GmbH) and
were sequenced in the Columbia University Sequencing
Facility using various IVa2 primers.
Nuclear extracts
A modification of the method described by Zhang and
Imperiale (2000) was used. 293A cells in 10-cm plates were
infected at a MOI of 5. Twenty-four hours after infection,
cells were washed twice with PBS, resuspended in 4 pellet
volumes of buffer A (10 mM HEPES, pH 7; 10 mM KCl;
1.5 mM MgCl2; 5 mM dithiothreitol [DTT], one protease
inhibitors tablet per 50 ml of buffer) and incubated on ice
for 1 h. The cells were then transferred to a glass Dounce
homogenizer and subjected to 20 strokes of a tight-fitting
pestle. The nuclei were centrifuged at 2000  g for 5 min at
4 jC. After being washed once with 1 ml of buffer A, the
nuclei were resuspended in 3 pellet volumes of buffer B (20
mM HEPES, pH 7.9; 20% glycerol; 420 mM NaCl; 1.5 mM
MgCl2; 0.2 mM EDTA; 5 mM DTT; one protease inhib-
itors tablet per 50 ml of buffer) and incubated on ice for
30 min. The supernatant was collected after centrifugation
at 12000  g for 10 min, frozen on dry ice, and stored in
aliquots of f200 Al at 80 jC.Electrophoretic mobility shift assays
Annealing and labeling of oligonucleotides
In order to develop a nonradioactive method for electro-
phoretic mobility shift assays (EMSA), a pair of comple-
mentary oligonucleotides spanning the IVa2-binding DE1
and DE2 elements were designed so that the annealed
duplex had 5V extensions of T’s. For the WT sequence,
oligonucleotides oAP50 (5VTTTTTCTAAGATTGTCAGT-
TTCCAAAAACGAGGAGGATTTGATATTCACCTG3V)
and oAP51 (5VTTTTTCAGGTGAATATCAAATCCTCCT-
CGTTTTTGG AAACTGACAATCTTAG3V), and for the
mutated sequence, oAP52 (5VTTTTTCTAA GgTtaTCcGTc-
TCCAAAAAgctactGctTTTtATATTCACCTG3V) and
oAP53 (5VTTTTT CAGGTGAATATaAAAagCagtagcTTT-
TTGGAgACgGAtAAcCTTAG3V) were heated at 70 jC for
10 min in TE and allowed to cool slowly. The duplexes were
labeled at both ends using a dNTP mixture that contains
biotinylated dATP (New England BioLabs Inc.) in a reaction
with T4 DNA polymerase. After incubating for 20 min at
room temperature, the enzyme was inactivated at 75 jC for
10 min and then allowed to cool slowly.
Binding of protein IVa2 to DE1/2 duplexes
Nuclear extracts from vWT- or vIVa2-infected cells and
from uninfected cells were incubated in 5 binding buffer
(20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT,
280 mM NaCl, 50 mM Tris–HCl, pH 7.5) with 1 Ag Poly
dI-dC per 10 Al reaction for 10 min at room temperature,
then the biotin-labeled duplex oligonucleotides were added
to the reaction and incubated for a further 20 min. Compe-
tition experiments were performed by pre-incubating the
extracts with increasing concentrations of the nonlabeled
WT or mutant duplex oligonucleotide. After adding 10
loading buffer (250 mM Tris–HCl, pH 7.5, 40% glycerol),
the samples were separated by electrophoresis on 6% TBE
gels (PAGEr Gold Precast Gels, Cambrex Bio Science Inc.,)
at 250 V in the cold room until the bromophenol blue
running in a marker lane had traveled 3/4 the height of the
gel (approximately 20 min). The gel was transferred via
capillary action for at least 3 h to a nylon membrane
(NytranN, Schleicher and Schuell) in 20 SSC. The filters
were processed and developed as for Southern blotting
analysis.
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